Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Charles River Laboratories Intl. Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $48.01, while Charles River Laboratories Intl. Inc trades at $228.43 (market cap $11.14B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | CRL | |
|---|---|---|
52-Week High | $49.91 | $233.60 |
52-Week Low | $47.57 | $145.57 |
Market Cap | — | $11.14B |
Sector | — | Health |
Enterprise Value | — | $14.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.89, down 0.4% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators but faces pressure from rising bond yields and Fed uncertainty. Recent news highlights strong bond ETF inflows as investors seek yield amid market volatility, though inflation concerns persist.
Outlook remains cautious due to potential Fed rate hikes and macroeconomic headwinds. The fund offers steady income through dividends but faces valuation pressure from rising rates. Key risks include interest rate sensitivity and global economic shifts impacting international bond performance.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
